How may anticancer chemotherapy with fluorouracil be individualised? (Q36486034)

14 August 2017

1 reference

title

How may anticancer chemotherapy with fluorouracil be individualised? (English)

1 reference

14 August 2017

1 reference

1 reference

Su-arpa Ploylearmsaeng

series ordinal

1

1 reference

14 August 2017

Uwe Fuhr

series ordinal

2

1 reference

14 August 2017

Alexander Jetter

series ordinal

3

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

Clinical Pharmacokinetics

14 August 2017

1 reference

14 August 2017

45

1 reference

14 August 2017

6

1 reference

14 August 2017

567-592

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200645060-00002

14 August 2017

0 references

cites work

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200645060-00002

Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.

21 January 2018

1 reference

12 December 2020

Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.

1 reference

12 December 2020

Urinary pyrimidine analysis in healthy newborns, infants, children, adults and patients with congenital metabolic diseases

1 reference

12 December 2020

Thymidylate synthase expression in stage II and III colon cancer: a retrospective review

1 reference

12 December 2020

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin

1 reference

12 December 2020

Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria

1 reference

12 December 2020

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

1 reference

12 December 2020

Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance

1 reference

12 December 2020

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

1 reference

12 December 2020

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy

1 reference

12 December 2020

Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients

1 reference

12 December 2020

Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results

1 reference

12 December 2020

Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy

1 reference

12 December 2020

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

12 December 2020

Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity

1 reference

12 December 2020

Regional assignment of the human thymidylate synthase (TS) gene to chromosome band 18p11.32 by nonisotopic in situ hybridization

1 reference

12 December 2020

Structural organization of the human dihydropyrimidine dehydrogenase gene

1 reference

12 December 2020

Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.

1 reference

12 December 2020

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

12 December 2020

Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer

1 reference

12 December 2020

Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations

1 reference

12 December 2020

Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer

1 reference

12 December 2020

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer

1 reference

12 December 2020

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

1 reference

12 December 2020

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

1 reference

12 December 2020

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

12 December 2020

Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity

1 reference

12 December 2020

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

1 reference

12 December 2020

Dose and time dependencies of 5-fluorouracil pharmacokinetics

1 reference

12 December 2020

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

1 reference

12 December 2020

Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine

1 reference

12 December 2020

Influence of sex and age on fluorouracil clearance

1 reference

12 December 2020

Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

1 reference

12 December 2020

Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene

1 reference

12 December 2020

Drugs of choice for cancer chemotherapy

1 reference

12 December 2020

Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function

1 reference

12 December 2020

Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene

1 reference

12 December 2020

Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure

1 reference

12 December 2020

Current treatments and future perspectives in colorectal and gastric cancer

1 reference

12 December 2020

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.

1 reference

12 December 2020

Relevance of pheno- and genotyping in clinical drug development.

1 reference

12 December 2020

Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration

1 reference

12 December 2020

Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels

1 reference

12 December 2020

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1 reference

12 December 2020

Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity

1 reference

12 December 2020

Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients

1 reference

12 December 2020

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli

1 reference

12 December 2020

Genetic factors influencing pyrimidine-antagonist chemotherapy.

1 reference

12 December 2020

Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen

1 reference

12 December 2020

Oesophageal cancer: new developments in systemic therapy

1 reference

12 December 2020

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

12 December 2020

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.

1 reference

12 December 2020

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W

1 reference

12 December 2020

Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.

1 reference

12 December 2020

Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

1 reference

12 December 2020

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy

1 reference

12 December 2020

Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test

1 reference

12 December 2020

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

1 reference

12 December 2020

Platinum-based chemotherapy in metastatic breast cancer: current status.

1 reference

12 December 2020

Review article: colorectal cancer chemotherapy

1 reference

12 December 2020

Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits

1 reference

12 December 2020

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

12 December 2020

Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance

1 reference

12 December 2020

Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without int

1 reference

12 December 2020

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas

1 reference

12 December 2020

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

1 reference

12 December 2020

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

12 December 2020

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

1 reference

12 December 2020

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

1 reference

12 December 2020

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

1 reference

12 December 2020

Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

12 December 2020

Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics.

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy

1 reference

12 December 2020

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus

1 reference

12 December 2020

Characterization of the human dihydropyrimidine dehydrogenase gene

1 reference

12 December 2020

cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli.

1 reference

12 December 2020

New systemic frontline treatment for metastatic colorectal carcinoma

1 reference

12 December 2020

Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio

1 reference

12 December 2020

Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity

1 reference

12 December 2020

Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant

1 reference

12 December 2020

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

1 reference

12 December 2020

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

1 reference

12 December 2020

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

1 reference

12 December 2020

Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

1 reference

12 December 2020

MTHFR (C677T) polymorphisms and stage III colon cancer: response to therapy

1 reference

12 December 2020

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

1 reference

12 December 2020

Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene

1 reference

12 December 2020

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

1 reference

12 December 2020

New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.

1 reference

12 December 2020

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

12 December 2020

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity

1 reference

12 December 2020

The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.

1 reference

12 December 2020

Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy.

1 reference

12 December 2020

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil

1 reference

12 December 2020

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients

1 reference

12 December 2020

Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines

1 reference

12 December 2020

Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

1 reference

12 December 2020

Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

1 reference

12 December 2020

Technologies for detecting genetic polymorphisms in pharmacogenomics

1 reference

12 December 2020

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

1 reference

12 December 2020

Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis

1 reference

12 December 2020

No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil

1 reference

12 December 2020

Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

10.2165/00003088-200645060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference